Abstract
There are different insulin analogues with various pharmacokinetic characteristics, such as, rapid-acting, long-acting, or intermediate-acting analogues. Since insulin tends to form amyloid aggregates, it is of particular interest to measure characteristic times of formation of amyloid aggregates and compare those to action times for insulin and its analogues. For the study we have chosen one of the insulin analogues - insulin Lispro, which is a fast acting insulin analog. It is usually thought of amyloid aggregation as a nucleation-dependent process. We have estimated the size of the primary nucleus to be one monomer and the size of the secondary nucleus to be around zero in both insulin and Lispro insulin aggregation processes. The main structural element of insulin and Lispro insulin amyloid fibrils is a rounded ring oligomer of about 6-7 nm in diameter, about 2-3 nm in height and about 2 nm in diameter of the hole. Fibrils of several μm in length are produced due to interaction of such oligomers. The packing of ring oligomers in fibrils differs because of the difference in their orderliness. Though the initial stages of fibril formation (monomer, oligomer) are similar, the further process depends on the unique sequence of each peptide. Namely the sequence affects the final morphology of mature amyloids. These observations allow us to conclude that formation of fibrils by short peptides occurs via and by means of oligomer ring structures. Such an important issue as the nature of polymorphism of insulin amyloid fibrils has been settled by us. The role of early oligomeric aggregates in such processes as nucleation and aggregation of amyloid fibrils has been examined.
Keywords: Amyloid, insulin, oligomer, nucleus, seed, mutation.
Graphical Abstract
Current Protein & Peptide Science
Title:Insulin and Lispro Insulin: What is Common and Different in their Behavior?
Volume: 18 Issue: 1
Author(s): Olga M. Selivanova, Mariya Yu. Suvorina, Alexey K. Surin, Nikita V. Dovidchenko and Oxana V. Galzitskaya
Affiliation:
Keywords: Amyloid, insulin, oligomer, nucleus, seed, mutation.
Abstract: There are different insulin analogues with various pharmacokinetic characteristics, such as, rapid-acting, long-acting, or intermediate-acting analogues. Since insulin tends to form amyloid aggregates, it is of particular interest to measure characteristic times of formation of amyloid aggregates and compare those to action times for insulin and its analogues. For the study we have chosen one of the insulin analogues - insulin Lispro, which is a fast acting insulin analog. It is usually thought of amyloid aggregation as a nucleation-dependent process. We have estimated the size of the primary nucleus to be one monomer and the size of the secondary nucleus to be around zero in both insulin and Lispro insulin aggregation processes. The main structural element of insulin and Lispro insulin amyloid fibrils is a rounded ring oligomer of about 6-7 nm in diameter, about 2-3 nm in height and about 2 nm in diameter of the hole. Fibrils of several μm in length are produced due to interaction of such oligomers. The packing of ring oligomers in fibrils differs because of the difference in their orderliness. Though the initial stages of fibril formation (monomer, oligomer) are similar, the further process depends on the unique sequence of each peptide. Namely the sequence affects the final morphology of mature amyloids. These observations allow us to conclude that formation of fibrils by short peptides occurs via and by means of oligomer ring structures. Such an important issue as the nature of polymorphism of insulin amyloid fibrils has been settled by us. The role of early oligomeric aggregates in such processes as nucleation and aggregation of amyloid fibrils has been examined.
Export Options
About this article
Cite this article as:
Selivanova M. Olga, Suvorina Yu. Mariya, Surin K. Alexey, Dovidchenko V. Nikita and Galzitskaya V. Oxana, Insulin and Lispro Insulin: What is Common and Different in their Behavior?, Current Protein & Peptide Science 2017; 18 (1) . https://dx.doi.org/10.2174/1389203717666160526122421
DOI https://dx.doi.org/10.2174/1389203717666160526122421 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes
Current Neurovascular Research Editorial (Thematic Issue: New Mechanisms and Targets for IBD Therapy: Translational Gastroenterology Comes of Age)
Current Drug Targets Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Current Medicinal Chemistry Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs
Current Medicinal Chemistry Effect of Passion Fruit (Passiflora edulis f. flavicarpa deg.) Peel Flour on the Prognosis of Acute Pancreatitis after Overnutrition During Lactation
The Natural Products Journal Essential Oils Downregulate Pro-Inflammatory Cytokines and Nitric Oxide-Mediated Oxidative Stress in Alloxan-Induced Diabetogenic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Silent Cerebral Damage in Hypertension
Current Hypertension Reviews Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects
Current Medicinal Chemistry An Engrossing History of Azidothymidine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Novel Oral Anticoagulants in Peripheral Arterial and Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Anemia in Chronic Heart Failure - Clinical and Prognostic Significance
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules
Current Topics in Medicinal Chemistry Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research Editorial
Recent Patents on Anti-Cancer Drug Discovery Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design